IE914137A1 - Solid dosage forms of almokalant and processes for¹manufacture thereof - Google Patents
Solid dosage forms of almokalant and processes for¹manufacture thereofInfo
- Publication number
- IE914137A1 IE914137A1 IE413791A IE413791A IE914137A1 IE 914137 A1 IE914137 A1 IE 914137A1 IE 413791 A IE413791 A IE 413791A IE 413791 A IE413791 A IE 413791A IE 914137 A1 IE914137 A1 IE 914137A1
- Authority
- IE
- Ireland
- Prior art keywords
- almokalant
- tablets
- tablet
- composition according
- solid dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/795—Polymers containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Chemical Treatment Of Metals (AREA)
Abstract
Solid oral pharmaceutical dosage forms containing a complex of almokalant as well as processes for their manufacture.
Description
Field of the invention This invention relates to solid dosage forms of the antiarrhythmic drug almokalant (p-INN) formulated as immediate release (IR) tablets and extended release (ER) tablets as well as processes for manufacture thereof.
Specifically the invention relates to the use of the polystyrene sulphonate complex of almokalant in solid dosage forms.
Background of the invention No solid dosage forms containing the polystyrene sulphonate complex of almokalant have been reported. The polystyrene sulphonate complex of almokalant is described in European patent application EP 90840242.0 (Publication No. 0404747 Al), which was not publicly available at the time of filing the basic application in Sweden, but was published shortly thereafter.
Almokalant (p-INN), 4-[3-[ethyl[3-(propylsulfinyl) propy1]amino]-2-hydroxypropoxy]-benzonitrile free base is a viscous, sticky substance, problematic to handle in the manufacture of solid dosage forms. It has pronounced tendency to give a repellent odorous degradation product with a smell resembling old onions.
Several different method of preparing a solid dosage form of almokalant have been tested. Commonly used methods had the following disadvantages.
Due to the instability of the base and its tendency to worsen tablet binding properties, solid dosage forms of the free base are difficult to produce. See further reference example III.
Tablets prepared by conventional technique, with almokalant dissolved in an acidic granulating solution, have inferior stability properties and develop a repelling onion-like odour. See further reference examples I and III.
The use of complexes of drug substances with ion exchange resins in pharmaceutical formulations has been described previously. A way to obtain a controlled release suspension containing codeine is described by Amsel L.P. et al Unique Oral Controlled Release Systems: In-Vivo Drug Release Pattern pp 83-93 where a complex between codeine and an ion exchange resin is coated with a diffusion membrane and then formulated into a suspension. In addition, Pennwalt Corporation has published a series of 2q patents describing the use of ion exchange resins having pharmacologically active substances absorbed thereon for use in controlled release preparations either as such or further coated with diffusion membranes (US Pat 4,221,778, EP 0171 528, EP 0 254 811). Other uses of ion exchange resin complexes with drugs in pharmaceutical formulations are for example summarized by Raghunathan et al. J Pharm Sci 1981, 70, (No 4), 379-384.
Description of the invention The aim of the present invention is to provide solid dosage forms of the antiarrhythmic drug almokalant, formulated as IR-tablets and ER-tablets with improved stability and minimal odour. ER-tablets can be formulated by a variety of formulation principles, such as for instance hydrophilic gel-matrix tablets, matrix tablets, membrane diffusion controlled formulations, osmotic pressure controlled dosage forms etc. - 3 As the use of solid substances in tablet manufacture in general is advantageous and facilitates the production, different ways of preparing solid dosage forms have been investigated.
As it was noticed that the compound almokalant as such in acidic solutions has a good stability, which makes it possible to autoclave it without noteworthy degradation, the addition of acid compounds was tested.
Although complex-binding to ion-exchange resins of viscous, 10 unstable, pharmacologically active agents, to form a stable solid complex suitable for pharmaceutical processing has not been previously described, this was tested with almokalant.
Thus, it was tested to use the polystyrene sulfonate 15 complex of almokalant in the formulation of pharmaceutical dosage forms. It was then unexpectedly found that almokalant polystyrene sulphonate complex (A-PSS) had a much better stability, less repelling odour and was much easier to handle in tablet manufacture.
To form ER tablets it is necessary to mix the formed complex with e.g. a hydrophilic matrix. It is especially preferable to use hydroxypropyl methylcellulose as the gel forming substance. It is further preferred to use a mixture of HPMC containing both low and high molecular weight HPMC.
The use of different mixtures of HPMC gives according to known technics (Journal of Controlled release, 5 (1987) 159-172), different release rates of the active ingredient almokalant.
EXAMPLES Example 1 Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water.
After drying the granulate was milled and then mixed with sodium stearyl fumarate and compressed to tablets.
A reference preparation was produced by dissolving the free base in a 2M hydrochloric acid solution and using this solution to granulate the excipients.
A-PSS tablet Ref. Ex 1 Ex I 1. A-PSS corresp. to almokalant 50.0 Almokalant - 50.0 2. Lactose pwd 84.5 Lactose anhydrous - 106.8 Avicel® PH 101 91.3 114.0 Povidone® K-25 26.8 Polyvinyl pyrrolidone, cross-linked - 7.1 Aerosil® - 3.6 3. Water, purified 105 Hydrochloric acid 2M - 71.2 (corresp. to HCl) - (5.2) 4. Sodium stearyl fumarate 5.8 Magnesium stearate - 2.9 Talcum - 11.5 Polyvinyl pyrrolidone, cross-linked - 5.7 The A-PSS tablet was prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to IE 916137 tablets was performed on a Korsch Pharmapress 100.
The reference tablet (Ref. ex. I) was prepared by making a granulating solution of the ingredients 1 and 3. The powders in 2 were mixed and then granulated with the prepared solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets compressed on the same machine.
A-PSS tablet. Ref.ex. I Ex. 1 Punches: 9 mm 10 mm Tablet weight: 298 mg 307 mg Hardness: 7.5 kP 6.7 kP 15 Disintegration: 1-2 min. 1-2 min. Ex. 1 Ref. A-PSS tablet Ex. I 20 Stability data of storage in glass bottles. Degradation measured as area sum of byproducts in a HPLC-system 0 month 0.81 2.11 25 1 month in 25°C 0.88 2.83 1 month in 50°C 1.82 3.41 3.5 months in 25°C 0.88 2.87 Example 2 Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water. After drying the granulate was milled and then mixed with the lubricant sodium stearyl fumarate and then tablets were formed by compression.
IE 91/L A reference preparation (Ref. ex. II) was produced by dissolving the free base in an aqueous tartaric acid solution and using this solution to granulate the excipients.
A-PSS tablet Ref. tablet Ex 2 Ex II 1. A-PSS corresp. to almokalant 50.0 50.0 Almokalant 2. Lactose pwd 84.5 - Lactose anhydrous - 110.7 Avicel® PH 101 91.3 114.3 Polyvidone® K-25 26.8 - 3. Water, purified 105 57.1 Tartaric acid - 21.5 4. Sodium stearyl fumarate 5.8 6.0 Talcum - 12.0 Polyvinyl pyrrolidone, cross-linked - 12.0 Punches: 9 mm 10mm Tablet weight: 298 mg 331mg Hardness: 7.5 kP 5.9kP Disintegration: 1-2 min. 8min.
The A-PSS tablets were prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to tablets were performed on a Korsch Pharmapress 100.
The reference tablet (Ref. ex. II) was prepared by making a granulating solution of 1 and 3. The powders 2 were mixed and granulated with the solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets were compressed on the same machine.
The odour intensity of the two formulations were compared IE 91k ΐ 37 immediately after manufacturing and after 1 month of storage in glass bottles.
Freshly prepared month Odour intensity A-PSS tablets Ex. 2 + (some smell, but not of onions.) + (some smell, but not of onions.) Ref.
Ex. II ++ (pronounced smell of onions.) +++ (strong smell of of onions) Example 3 Immediate release tablets of almokalant can be prepared in suitable strengths.
In Ex. 1 and 2 a 50 mg preparation was described. Below are examples of 70 mg and 1.8 mg preparations shown.
Ex 3a 70 mg Ex 3b 1.8 mg 1. A-PSS 127 Avicel® PH 101 148 Polyvidone® K-90 35 2. Polyvidone® K-90 10 Polyvidone® K-25 Water, purified 161 3.3 3. Avicel® PH102 coarse grade Polyvinyl pyrrolidone, cross-linked Sodium stearyl fumarate 4.7 107 1.6 4.3 1.4 The A-PSS tablets were prepared by first mixing the ingredients 1. The mixture was granulated with a solution made of ingredients 2. After drying and milling ingredients 3 were admixed, whereupon compression to 5 tablets were performed on a Korsch Pharmapress 100.
Punches: mm 5.5x10.5 mm Tablet weight: Hardness: Disintegration (without discs): 322 mg 9-10 kP 0.6-1.0 min. 150 mg 9-10 kP 0.2-0.4 min.
Example 4 Extended release tablets of almokalant were prepared by mixing A-PSS 95 parts, hydroxypropyl methylcellulose (HPMC) 50 cps 40 parts, HPMC 10000 cps 160 parts and hydroxypropyl cellulose (HPC) 50 parts and then granulating the mixture with ethanol 99.5%. After drying the granulate was milled and then mixed with sodium stearyl fumarate whereupon compression to tablets was done.
A reference preparation (Ref. ex. Ill) was made by dissolving the free base in ethanol (99.5%) and using this solution to granulate the dry excipients, and otherwise following the same way of production.
Example 4 Ref.ex. Ill Ingredient mg/tablet mg/tablet 1. A-PSS corresp. to almokalant Almokalant 2. HPMC 50 cps (Metolose® 60SH50) 50.0 40.0 50.0 40.0 IE 91+137 3. HPMC 10000 cps (Methocel E10MCR) 160.0 160.0 4. HPC LF (Klucel® LF) 50.0 50.0 . Ethanol 99.5% 261 235 6. Sodium stearyl fumarate (Pruv®) 3.3 3.3 Ingredients 1 to 4 were mixed. The mixture was granulated with ethanol. After drying and milling the granulate was mixed with 6.
Compression to tablets was performed on a Korsch Pharmapress 100 with 11 mm circular punches. The tablet machine was equipped with compression force registration.
Tablet weight: 348 mg 303 mg 15 It compression force: 8.6 kN 12.3 kN II hardness: 5.5 kP 3.7 kP Tablets made using the free base have inferior binding properties.
Odour intensity A-PSS tablets (Ex. 4) Reference tablet (Ref.ex. Ill) Freshly prepared + (some smell, but not of onions.) +++ (strong smell of onions.) The release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle, 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium. 91 z 137 10 A-PSS tablet (Ex. 4) Ref. tablet (Ref.ex. Ill) cumulative cumulative 5 hours % released % released average (min-max) average (min-max) 2 15 (14-15) 28 (28-29) 4 24 (23-25) 43 (42-43) 10 6 34 (33-35) 55 (54-56) 10 51 (48-52) 74 (72.-75) 24 91 (87-93) 102(100-105) Example 5 Extended release tablets of almokalant can be prepared in suitable strengths and with different release rates. In Ex. 4 a preparation with 50 mg strength is described. Below follows examples of 10 mg and 100 mg. 10 mg 100 mg Ex. 5a Ex. 5b Ingredient mg/tablet 1. A-PSS corresp. to almokalant 10.0 100.0 2. Lactose pwd 100.0 40.0 HPMC 50 cps (Metolose® 60SH50) 27.6 39.2 HPMC lOOOOcps (Methocel® E10MCR) 110.4 146.4 HPC LF (Klucel® LF) 25.0 - 3. Polyethylene glycol 20M (Carbowax® 20M) 30.0 Polyethylene glycol 6000 (Carbowax® 6000) 42.0 4. Water, purified 70.0 98.1 5. Sodium stearyl fumarate (Pruv ) 1.6 2.3 IE 9111 and 2 were mixed. The mixture was granulated with a solution made of 3 and 4. After drying and milling the granulate was mixed with 5.
Compression Pharmapress compression to tablets was performed on a Korsch 100. The tablet machine was equipped with force registration.
Punches, diameter: 10 mm 11 mm Tablet weight: 314 mg 459 mg compression force (kN): 11.0 11.4 hardness (kP): 8.2 5.4 The release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium. mg ER tablet 100 mg ER tablet EX. 5a Ex. 5b cumulative cumulative 25 hours % released % released average (min-max) average (min-max) 2 27 (27-28) 17 (17-18) 4 44 (43-45) 28 (26-29) 30 6 37 (35-39) 8 72 (70-75) 10 55 (52-60) 12 105 (96-109) 20 91 (84-95) 35 24 100(99-101) ΙΕ 3Φ Ί37 Examples 6-7 Controlled release tablets were prepared by granulating 54.3 parts active substance, 30.0 parts mannitol, 154 parts HPMC 50 cps, 221 parts HPMC 10,000 cps, 37.5 parts HPC, 0.3 parts propyl gallate with a solution of 45 parts PEG 20,000 (Ex. 6} or PVP K-25 (Ex. 7) dissolved in 105 parts of water. The dried granulate was lubricated with 2.7 parts of sodium stearyl fumarate.
Ingredient Example 6 mg/tablet Example 7 1. A-PSS corresp. to almokalant 30.0 30.0 2. Mannitol pwd 30.0 30.0 3. HPMC (Metolose® 60SH50) 154.0 154.0 20 4. HPMC (Methocel® E10MCR) 221.0 221.0 5. HPC (Klucel® LF) 37.5 37.5 6. Propyl gallate 0.3 0.3 7. PEG (Carbowax® 20M) 45.0 - PVP (Povidone® K-25) - 45.0 25 8. Water 105.0 105.0 9. Sodium stearyl fumarate (Pruv®) 2.7 2.7 Ingredients 1 to 6 were mixed. The mixture was granulated with a solution made of 7 and 8. After drying the granulate was mixed with 9.
Compression to tablets were performed on a Korsch Pharmapress 100 with 11 mm circular punches. The tablet machine was equipped with compression force registration Example 6 Example 7 Tablet weight: 545 mg 545 mg IE 91'137 compression force (kN): 20 19 tablet hardness (kP): 7.7 12.2 The release rate was determined in USP dissolution 5 apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
Cumulative % released Average (min-max) Example 6 Example 7 2h 17(17-18) 18(17-18) 4h 28(28-29) 28(28-29) 6h 38(38-39) 38(37-39) lOh 55(54-56) 54(53-56) 16h 74(73-76) 73(71-74) The examples show that PEG 20000 and PV function in the process.
Discussion From the examples it can be seen that the use of almokalant free base in pharmaceutical formulations - apart from the inconvenience of handling a sticky, viscous substance results in dosage forms with inferior stability and palatability as well as in inferior technical properties. The use of almokalant polystyrene sulphonate complex in pharmaceutical formulations eases the handling and results in more stable and more palatable dosage forms.
The best mode of carrying out the invention known at present is to prepare the formulation according to Examples 6-7.
Claims (11)
1. An orally administrable pharmaceutical composition of almokalant in solid dosage form, which comprises a complex of almokalant with polystyrene 5 sulphonate, and optionally one or more pharmaceutical excipients.
2. A composition according to claim 1 which contains, as pharmaceutical excipient, a hydrophilic matrix. 10
3. A composition according to claim 2 wherein the hydrophilic matrix is hydroxypropyl methylcellulose.
4. A composition according to claim 3 wherein the hydroxypropyl methylcellulose contains both low and high molecular weight hydroxypropyl methylcellulose. 15
5. A composition according to any one of the preceding claims in tablet form.
6. A composition according to claim 1 substantially as hereinbefore described.
7. A composition according to claim 1 20 substantially as described in any one of the Examples.
8. A process for the manufacture of a composition as claimed in any preceding claim, which process comprises reacting almokalant with polystyrene sulphonic acid to form a complex, optionally mixing the complex with one or more 25 pharmaceutical excipients, and forming into orally administrable solid dosage form in manner known per se.
9. A process according to claim 8, wherein there is used, as pharmaceutical excipient, a hydrophilic matrix.
10. A process according to claim 9, wherein the 30 hydrophilic matrix is hydroxypropyl methylcellulose.
11. A composition according to claim 1 made by the process claimed in any one of claims 8 to 10.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9003902A SE9003902D0 (en) | 1990-12-07 | 1990-12-07 | SOLID DOSAGE FORMS OF A DRUG |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE914137A1 true IE914137A1 (en) | 1992-06-17 |
Family
ID=20381121
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE413791A IE914137A1 (en) | 1990-12-07 | 1991-11-28 | Solid dosage forms of almokalant and processes for¹manufacture thereof |
Country Status (26)
| Country | Link |
|---|---|
| EP (1) | EP0560821A1 (en) |
| JP (1) | JPH06503312A (en) |
| CN (1) | CN1063039A (en) |
| AP (1) | AP258A (en) |
| AU (1) | AU8930791A (en) |
| BG (1) | BG97851A (en) |
| CA (1) | CA2097178A1 (en) |
| CZ (1) | CZ103793A3 (en) |
| FI (1) | FI932554A (en) |
| HU (1) | HUT64217A (en) |
| IE (1) | IE914137A1 (en) |
| IL (1) | IL100150A0 (en) |
| IS (1) | IS3788A7 (en) |
| LT (1) | LTIP1717A (en) |
| MA (1) | MA22355A1 (en) |
| MX (1) | MX9102325A (en) |
| MY (1) | MY106776A (en) |
| NZ (1) | NZ240731A (en) |
| PT (1) | PT99719A (en) |
| SE (1) | SE9003902D0 (en) |
| SK (1) | SK55693A3 (en) |
| TN (1) | TNSN91117A1 (en) |
| TW (1) | TW215057B (en) |
| WO (1) | WO1992010172A1 (en) |
| YU (1) | YU186891A (en) |
| ZA (1) | ZA919264B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19602757A1 (en) * | 1996-01-26 | 1997-07-31 | Boehringer Mannheim Gmbh | Solid instant release dosage forms and processes for their manufacture |
| GB9611328D0 (en) * | 1996-05-31 | 1996-08-07 | Zeneca Ltd | Pharmaceutical compositions |
| US6024981A (en) * | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| JP4504467B2 (en) * | 1998-07-30 | 2010-07-14 | 佐藤製薬株式会社 | Orally disintegrating tablets |
| JP7426685B2 (en) * | 2018-06-14 | 2024-02-02 | 株式会社東洋新薬 | tablet |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8705150D0 (en) * | 1987-12-23 | 1987-12-23 | Haessle Ab | NOVEL ANTIARRHYTHMIC AGENTS |
| IL90245A (en) * | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it |
| SE8902236D0 (en) * | 1989-06-20 | 1989-06-20 | Haessle Ab | NOVEL POLYSTYRENESULPHONATE |
-
1990
- 1990-12-07 SE SE9003902A patent/SE9003902D0/en unknown
-
1991
- 1991-11-22 ZA ZA919264A patent/ZA919264B/en unknown
- 1991-11-25 TW TW080109239A patent/TW215057B/zh active
- 1991-11-25 IL IL100150A patent/IL100150A0/en unknown
- 1991-11-26 NZ NZ240731A patent/NZ240731A/en unknown
- 1991-11-27 YU YU186891A patent/YU186891A/en unknown
- 1991-11-28 IE IE413791A patent/IE914137A1/en unknown
- 1991-12-02 AP APAP/P/1991/000338A patent/AP258A/en active
- 1991-12-02 MX MX9102325A patent/MX9102325A/en unknown
- 1991-12-03 WO PCT/SE1991/000815 patent/WO1992010172A1/en not_active Application Discontinuation
- 1991-12-03 JP JP4500117A patent/JPH06503312A/en active Pending
- 1991-12-03 CZ CS931037A patent/CZ103793A3/en unknown
- 1991-12-03 CA CA002097178A patent/CA2097178A1/en not_active Abandoned
- 1991-12-03 SK SK55693A patent/SK55693A3/en unknown
- 1991-12-03 MA MA22639A patent/MA22355A1/en unknown
- 1991-12-03 HU HU9301670A patent/HUT64217A/en unknown
- 1991-12-03 AU AU89307/91A patent/AU8930791A/en not_active Abandoned
- 1991-12-03 EP EP91920708A patent/EP0560821A1/en not_active Withdrawn
- 1991-12-06 PT PT99719A patent/PT99719A/en not_active Application Discontinuation
- 1991-12-06 IS IS3788A patent/IS3788A7/en unknown
- 1991-12-06 MY MYPI91002267A patent/MY106776A/en unknown
- 1991-12-06 TN TNTNSN91117A patent/TNSN91117A1/en unknown
- 1991-12-07 CN CN91112789A patent/CN1063039A/en active Pending
-
1993
- 1993-06-04 FI FI932554A patent/FI932554A/en not_active Application Discontinuation
- 1993-06-04 BG BG97851A patent/BG97851A/en unknown
- 1993-12-30 LT LTIP1717A patent/LTIP1717A/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0560821A1 (en) | 1993-09-22 |
| NZ240731A (en) | 1993-10-26 |
| SK55693A3 (en) | 1993-10-06 |
| ZA919264B (en) | 1992-08-26 |
| LTIP1717A (en) | 1995-07-25 |
| CA2097178A1 (en) | 1992-06-08 |
| CZ103793A3 (en) | 1994-02-16 |
| AP9100338A0 (en) | 1992-01-31 |
| SE9003902D0 (en) | 1990-12-07 |
| MY106776A (en) | 1995-07-31 |
| WO1992010172A1 (en) | 1992-06-25 |
| BG97851A (en) | 1994-04-29 |
| JPH06503312A (en) | 1994-04-14 |
| MA22355A1 (en) | 1992-07-01 |
| YU186891A (en) | 1994-04-05 |
| HU9301670D0 (en) | 1993-09-28 |
| MX9102325A (en) | 1992-06-01 |
| IS3788A7 (en) | 1992-06-08 |
| IL100150A0 (en) | 1992-08-18 |
| CN1063039A (en) | 1992-07-29 |
| HUT64217A (en) | 1993-12-28 |
| FI932554A (en) | 1993-06-08 |
| FI932554A0 (en) | 1993-06-04 |
| TNSN91117A1 (en) | 1992-10-25 |
| TW215057B (en) | 1993-10-21 |
| PT99719A (en) | 1992-10-30 |
| AP258A (en) | 1993-06-03 |
| AU8930791A (en) | 1992-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7749536B2 (en) | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture | |
| US5972381A (en) | Solid solution of an antifungal agent with enhanced bioavailability | |
| US20020054903A1 (en) | Direct compression polymer tablet core | |
| US20090291135A1 (en) | Direct compression polymer tablet core | |
| KR101120729B1 (en) | Controlled-release compositions | |
| WO2003055475A1 (en) | Controlled release pharmaceutical formulation containing venlafaxine | |
| NO341321B1 (en) | Preparation for oral administration of tamsulosin hydrochloride and controlled release formulation granule comprising the same | |
| US20030118647A1 (en) | Extended release tablet of metformin | |
| RU2300368C2 (en) | Ibuprofen-containing composition | |
| JP5124286B2 (en) | Sustained release preparation and method for producing the same | |
| US5149523A (en) | Polystyrenesulfonate-drug complex and solid dosage forms thereof | |
| AP258A (en) | Solid dosage forms of almokalant and processes for manufacture thereof. | |
| EP1818048A1 (en) | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture | |
| EP0266707B1 (en) | Sustained release labetalol tablet | |
| EP1079834B1 (en) | Stable compositions comprising levosimendan and alginic acid | |
| US20050042279A1 (en) | Pharmaceutical formulation comprising more than 15% tamoxifen | |
| WO2003051364A1 (en) | Amlopidine bezylate tablets with improved stability | |
| CA2481377A1 (en) | Antihistamine-decongestant pharmaceutical compositions | |
| WO2023128903A1 (en) | Improved manufacturing method for formulations comprising amorphous tolvaptan | |
| CA2576135C (en) | Direct compression polymer tablet core | |
| KR20080093073A (en) | Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture |